Samsung Biologics to Spin Off Biosimilar Business

MT Newswires Live

May 22, 2025

Samsung Biologics (KRX:207940) is planning to separate its biosimilar and its contract development and manufacturing Organization (CDMO) business via a spin-off, according to a Thursday release.

The spin-off will result in the establishment of a new holding company, Samsung Epi Holdings, which will take full ownership of Samsung Bioepis. Samsung Bioepis CEO Kim Kyung-ah will head the new entity, the release said.

Meanwhile, Samsung Biologics will remain focused solely on its CDMO business.

The split will be finalized after shareholder approval on Sept. 16, with Samsung Epi Holdings' official launch set for Oct. 1. Both companies are scheduled to be listed separately on Oct. 29, it said.

Shares of Samsung Biologics fell nearly 2% at market close on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537991765"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537991765\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537991765?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 18:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537991765","market":"fut","top_or_hot":-1,"title":"Samsung Biologics to Spin Off Biosimilar Business","media":"MT Newswires Live","content":"<html><body><p> Samsung Biologics (KRX:207940) is planning to separate its biosimilar and its contract development and manufacturing Organization (CDMO) business via a spin-off, according to a Thursday release.</p><p>The spin-off will result in the establishment of a new holding company, Samsung Epi Holdings, which will take full ownership of Samsung Bioepis. Samsung Bioepis CEO Kim Kyung-ah will head the new entity, the release said.</p><p>Meanwhile, Samsung Biologics will remain focused solely on its CDMO business.</p><p>The split will be finalized after shareholder approval on Sept. 16, with Samsung Epi Holdings' official launch set for Oct. 1. Both companies are scheduled to be listed separately on Oct. 29, it said.</p><p>Shares of Samsung Biologics fell nearly 2% at market close on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsung Biologics to Spin Off Biosimilar Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsung Biologics to Spin Off Biosimilar Business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-22 18:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Samsung Biologics (KRX:207940) is planning to separate its biosimilar and its contract development and manufacturing Organization (CDMO) business via a spin-off, according to a Thursday release.</p><p>The spin-off will result in the establishment of a new holding company, Samsung Epi Holdings, which will take full ownership of Samsung Bioepis. Samsung Bioepis CEO Kim Kyung-ah will head the new entity, the release said.</p><p>Meanwhile, Samsung Biologics will remain focused solely on its CDMO business.</p><p>The split will be finalized after shareholder approval on Sept. 16, with Samsung Epi Holdings' official launch set for Oct. 1. Both companies are scheduled to be listed separately on Oct. 29, it said.</p><p>Shares of Samsung Biologics fell nearly 2% at market close on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2537991765","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537991765","pubTimestamp":1747908927,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Samsung Biologics  is planning to separate its biosimilar and its contract development and manufacturing Organization  business via a spin-off, according to a Thursday release.The spin-off will result in the establishment of a new holding company, Samsung Epi Holdings, which will take full ownership of Samsung Bioepis. Samsung Bioepis CEO Kim Kyung-ah will head the new entity, the release said.Meanwhile, Samsung Biologics will remain focused solely on its CDMO business.The split will be finalized after shareholder approval on Sept. 16, with Samsung Epi Holdings' official launch set for Oct. 1. Both companies are scheduled to be listed separately on Oct. 29, it said.Shares of Samsung Biologics fell nearly 2% at market close on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CDMO":"Avid Bioservices, Inc."},"translate_title":"三星生物制品将剥离生物仿制药业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":1},"content_text":"Samsung Biologics (KRX:207940) is planning to separate its biosimilar and its contract development and manufacturing Organization (CDMO) business via a spin-off, according to a Thursday release.The spin-off will result in the establishment of a new holding company, Samsung Epi Holdings, which will take full ownership of Samsung Bioepis. Samsung Bioepis CEO Kim Kyung-ah will head the new entity, the release said.Meanwhile, Samsung Biologics will remain focused solely on its CDMO business.The split will be finalized after shareholder approval on Sept. 16, with Samsung Epi Holdings' official launch set for Oct. 1. Both companies are scheduled to be listed separately on Oct. 29, it said.Shares of Samsung Biologics fell nearly 2% at market close on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}